Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus fruquintinib in immunocompetent MSS metastatic colorectal cancer (phase II)
ChiCTR2500112464Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 and fruquintinib in colorectal cancer (CRC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: objective remission rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
QL1706fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500112464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112464.